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Seroprevalence of Bordetella pertussis in healthcare workers in a Portuguese tertiary referral hospital
Background:
Bordetella pertussis causes an acute infectious
disease that, in newborns and little infants, can
present with severe clinical manifestations or
even death. The world prevalence is around 16
million cases per year, with 195.000 estimated
deaths.
In Portugal, whole cell pertussis vaccine was
introduced in 1965 followed, in 2006, by the
acellular form included in a triple vaccine
(diphteria, tetanus and pertussis). The national
vaccine coverage is about 95% and the program
includes 5 doses (2, 4, 6, 18 months, 5 years).
Yet a raising number of cases have been
observed, with an incidence of 2.14 per
100.000 cases in 2012. The emergence of this
disease in Portugal and in other countries can
be related with multiple factors: better
diagnostic tools (molecular techniques), genetic
evolution of Bordetella pertussis and the switch
from whole cell vaccine to the acellular form,
that seems to give less protection. Duration of
protection against Pertussis infection is
unknown (after last immunization or disease).
Healthcare professionals, working with
children, can be the source of infection of
hospital outbreaks. Knowing the
seroprevalence of pertussis antibodies among
them is important to reinforce the need for
vaccination in susceptible professionals.
Methods:
Prospective study including healthcare workers
from neonatology and pediatric departments
and clinical pathology laboratory of a tertiary
referral hospital (physicians, nurses, medical
auxiliars, laboratory technicians, administrative
assistants).
Demographic data (gender, age, professional
category, department) and last date of
Bordetella pertussis immunization (if possible)
were collected. People with acute respiratory
symptoms, pregnants or vaccinated with
pertussis during the year of 2016 were
excluded.
Seroprevalence for pertussis was tested through
IgG for pertussis toxin by ELISA
(Euroimmun®) and it was considered positive
(>100 UI/mL), negative (<40 UI/mL) or
equivocal (40-100 UI/mL). The equivocal
results were retested. Sensibility - 100%;
specificity - 95.5%. This study was approved
by the ethical committee of the hospital.
Results and Discussion:
Eighty percent (72/90) of the studied
population belonged to the female gender. The
distribution according to age groups is
presented in table 1, with 38% of persons
(34/90) between 35-45 years. Almost one third
were nurses (27/90), followed by physicians
(26/90), medical auxiliars (21/90), laboratory
technicians (8/90) and administrative
assistants (8/90), as exposed in table 2.
The table 2 also shows distribution
characteristics by deparment. People from
emergency room were the most participative
with 34% (31/90).
Almost ninety-eight percent (88/90) of the
population tested was negative for IgG
pertussis toxin. The two equivocal results in a
nurse (35-44 years, ER) and a physician (>45
years, neonatology department) were probably
due to cross-reactions.
Conclusions:
This population is all susceptible to pertussis
infection and a major reservoir for disease and
for its transmission. A booster immunization







Table 1- Demographic Data by age
Prof. category ER Neo. Dep. Cl. Practice Ped . Dep. Laboratory Total
Nurses 12 9 3 3 0 27
Physicians 9 5 3 7 2 26
Medical auxiliars 9 6 4 1 1 21
Lab. technicians 0 0 0 0 8 8
Administratives 1 2 4 1 0 8
Total 31 22 14 12 11 90
Table 2 - Demographic Data by professional category and department
Results (cont.):
Near 17% (15/90) were not vaccinated against
pertussis (> 50 years old) or, at least, did not
have it registered on vaccination records. Four
people loss their records. All the remaining
(70/90) had the last booster 20 years ago or
more, except one physician (25-34 years, ER)
that received a booster of acellular vaccine in
2006 but he was also negative for IgG.
We found no relation between gender, age,
professional category, years of vaccination and
seroprevalence.
